Table 2 Therapeutic approaches and outcomes

Thromboprophylaxis

 Unfractionated heparin

17 (11.9)

11 (9.8)

6 (19.4)

 Low-molecular weight heparin

31 (21.7)

20 (17.9)

11 (35.5)

 Unspecified

3 (2.1)

2 (1.8)

1 (3.2)

 Not received

89 (62.2)

77 (68.8)

12 (38.7)

Treatment

 Unfractionated heparin

28 (19.6)

22 (19.6)

6 (19.4)

 Low-molecular-weight-heparin

57 (39.9)

49 (43.8)

8 (25.8)

 Warfarin

0 (0)

0 (0)

0 (0)

 Fondaparinoux

3 (2.1)

3 (2.7)

0 (0)

 Direct-acting oral anticoagulants

8 (5.6)

8 (7.1)

0 (0)

  Apixaban

4 (2.8)

4 (3.6)

0 (0)

  Rivaroxaban

2 (1.4)

2 (1.8)

0 (0)

  Unspecified DOACs

2 (1.4)

2 (1.8)

0 (0)

 Alteplase 100 mg

33 (23.1)

20 (17.9)

13 (41.9)

 Alteplase 50 mg

6 (4.2)

4 (3.6)

2 (6.5)

 Tenecteplase

1 (0.7)

0 (0)

1 (3.2)

 Catheter-directed thrombolysis

1 (0.7)

1 (0.9)

0 (0)

 Ultrasound-facilitated catheter-directed thrombolysis

3 (2.1)

3 (2.7)

0 (0)

 Mechanical thrombectomy

3 (2.1)

3 (2.7)

0 (0)

 Surgical thrombectomy

4 (2.8)

3 (2.7)

1 (3.2)

Outcomes

 Death

31 (21.6)

112 (78.39)

31 (21.6)

 Intracranial hemorrhage

2 (1.4)

1 (0.9)

1 (3.2)

 Major bleeding

2 (1.4)

1 (0.9)

1 (3.2)

 Minor bleeding

2 (1.4)

1 (0.9)

1 (3.2)